ID
42476
Beschreibung
Study Title: LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients https://leoss.net Study Indication: COVID-19 Date: 19.03.2021 Published with permission by Prof. Dr. med. J.-J. Vehreschild. LEOSS, a multi-center cohort study, has been created to get more in-depth knowledge about the epidemiology and clinical course of patients infected with SARS-CoV-2. Initiated by the ESCMID Emerging Infections Task Force (EITaF) and the German Infectious Disease Society, and supported by all German Centers for Health Research (DZG), LEOSS has developed into an international network of contributors. Via an integrative research approach with anonymous recruitment and collection of routine data in an open science context, LEOSS is building a uniform clinical dataset and providing real-time analyses. For more information feel free to explore https://leoss.net/. Please note that only cases with known outcome are collected! Baseline / diagnosis is defined as the day the sample of the first positive SARS-CoV-2 result was taken. Criteria of the Uncomplicated Phase: Asymptomatic OR Symptoms of upper respiratory tract infection and/or Nausea, emesis, diarrhea and/or Fever Remember: The Uncomplicated Phase ends, if a previously febrile patient has no fever anymore and has completed 14 days of follow-up without entering Complicated or Critical Phase; then move to Recovery Phase. Also, as soon as one of the criteria of the Complicated or Critical Phase are fulfilled, Uncomplicated Phase ends; move over to there. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Complicated Phase: * Need for oxygen supplementation (In patients with prior oxygen home therapy, clinically meaningful increase in need for oxygenation.) * paO2 at room air < 70 mmHg * SO2 at room air < 90 % * GOT or GPT > 5x ULN * New cardiac arrhythmia * New pericardial effusion >1cm * New heart failure with pulmonary edema, congestive hepatopathy or peripheral edema Remember: The Complicated Phase ends, if none of the criteria for the Complicated Phase is fulfilled anymore AND the patient is free of fever; then move to Recovery Phase. Also, as soon as one of the criteria of the Critical Phase are fulfilled, Complicated Phase ends; move over to Critical Phase. If the patient has died, the phase ends with the death of the patient. If the patient has died, do not report terminal values, e.g. those recorded after switching off life-support or heart rate "0" after death of the patient. Criteria of the Critical Phase: * Need for catecholamines * Life-threatening cardiac arrhythmia * Mechanical ventilation (invasive or non-invasive) * Liver failure with Quick< 50% * qSOFA >= 2 * Renal failure in need of dialysis Remember: The Critical Phase ends as soon as none of the criteria for the Critical Phase is fulfilled anymore AND the patient is free of fever. If the patient has died, it ends with the death of the patient. If the patient has died, do not report terminal values, i.e. those recorded after turning off life-support or heart rate "0" after death of the patient. Criteria of the Recovery Phase: *Improvement by at least one phase, i.e. Critical to Complicated or Complicated to Uncomplicated * Defervescence Remember: Uncomplicated asymptomatic patients enter recovery phase after 14 days of observation without disease progression No further progression or re-hospitalization If a text field can't be filled out, note 'ND' (for not determined).
Link
Stichworte
Versionen (3)
- 02.07.21 02.07.21 - Sarah Riepenhausen
- 15.07.21 15.07.21 - Sarah Riepenhausen
- 16.07.21 16.07.21 - Sarah Riepenhausen
Rechteinhaber
LEOSS
Hochgeladen am
16. Juli 2021
DOI
10.21961/mdm:42476
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
LEOSS: Lean European Open Survey on SARS-CoV-2 Infected Patients
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
Beschreibung
Antibodies: CD-22
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0054947
Beschreibung
Antibodies: CD-38
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0075742
Beschreibung
Antibodies: CD-52
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1610534
Beschreibung
Antibodies: Anti-CD79b
Alias
- UMLS CUI-1
- C0104979
- UMLS CUI-2
- C0003241
Beschreibung
Antibodies: B Lymphocyte stimulator-specific inhibitor (BLyS)
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C3160093
Beschreibung
Antibodies: CD19-BiTE
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C4727095
Beschreibung
Antibodies: Complement inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1564892
Beschreibung
Crovalimab
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C1564892
- UMLS CUI [1,2]
- C3846158
Beschreibung
Eculizumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C1541483
Beschreibung
Pegcetacoplan (APL-2)
Datentyp
integer
Alias
- UMLS CUI [1]
- C4053680
Beschreibung
Ravulizumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C4550350
Beschreibung
Antibodies: Integrin antagonists
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C2917367
Beschreibung
Antibodies: Interleukin inhibitors
Alias
- UMLS CUI-1
- C3653320
- UMLS CUI-2
- C0003241
Beschreibung
Basiliximab
Datentyp
integer
Alias
- UMLS CUI [1]
- C0676831
Beschreibung
Canakinumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C2718773
Beschreibung
Ixekizumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C3489764
Beschreibung
Sarilumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C3885145
Beschreibung
Secukinumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C3179547
Beschreibung
Tocilizumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C1609165
Beschreibung
Ustekinumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C1608841
Beschreibung
Antibodies: TNF-alpha inhibitors
Alias
- UMLS CUI-1
- C3653350
- UMLS CUI-2
- C0003241
Beschreibung
Adalimumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C1122087
Beschreibung
Certolizumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C1872109
Beschreibung
Etanercept
Datentyp
integer
Alias
- UMLS CUI [1]
- C0717758
Beschreibung
Golimumab
Datentyp
integer
Alias
- UMLS CUI [1]
- C2353893
Beschreibung
Infliximab
Datentyp
integer
Alias
- UMLS CUI [1]
- C0666743
Beschreibung
Other Antibodies
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C0205394
Beschreibung
Inhibitors: Co-stimulation inhibitors
Alias
- UMLS CUI-1
- C0003241
- UMLS CUI-2
- C1622572
- UMLS CUI-3
- C1999216
Beschreibung
Inhibitors: Calcineurin inhibitors
Alias
- UMLS CUI-1
- C1562036
Beschreibung
Inhibitors: Interleukin inhibitor
Alias
- UMLS CUI-1
- C3653320
Beschreibung
Inhibitors: JAK inhibitors
Alias
- UMLS CUI-1
- C3854325
Beschreibung
Baricitinib
Datentyp
integer
Alias
- UMLS CUI [1]
- C4044947
Beschreibung
Fedratinib
Datentyp
integer
Alias
- UMLS CUI [1]
- C3886623
Beschreibung
Ruxolitinib
Datentyp
integer
Alias
- UMLS CUI [1]
- C2931926
Beschreibung
Tofacitinib
Datentyp
integer
Alias
- UMLS CUI [1]
- C2930696
Beschreibung
Upadacitinib
Datentyp
integer
Alias
- UMLS CUI [1]
- C4726929
Beschreibung
Inhibitors: mTOR inhibitors
Alias
- UMLS CUI-1
- C2746052
Beschreibung
Inhibitor: PDE-4-inhibitor
Alias
- UMLS CUI-1
- C2936609
Beschreibung
Other Inhibitors
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0243077
Beschreibung
Checkpoint inhibitors: last 3 months
Alias
- UMLS CUI-1
- C0332185
- UMLS CUI-2
- C4733472
Beschreibung
In case of combination therapy please indicate all of the respective drugs.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3657270
Beschreibung
In case of combination therapy please indicate all of the respective drugs.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C3658706
Beschreibung
In case of combination therapy please indicate all of the respective drugs.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C1367202
Beschreibung
In case of combination therapy please indicate all of the respective drugs.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
Beschreibung
Indicate recent other checkpoint inhibitor
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0332185
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C4733472
- UMLS CUI [1,4]
- C1521902
Beschreibung
No recent checkpoint inhibitor therapy
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C1298908
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Beschreibung
Unknown Checkpoint inhibitor therapy
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0439673
- UMLS CUI [1,2]
- C0332185
- UMLS CUI [1,3]
- C4733472
Beschreibung
Chemotherapeutics: Antimetabolites
Alias
- UMLS CUI-1
- C0003376
- UMLS CUI-2
- C0729502
Beschreibung
6-Mercaptopurine
Datentyp
integer
Alias
- UMLS CUI [1]
- C0000618
Beschreibung
Azathioprine
Datentyp
integer
Alias
- UMLS CUI [1]
- C0004482
Beschreibung
Leflunomide
Datentyp
integer
Alias
- UMLS CUI [1]
- C0063041
Beschreibung
Methotrexate
Datentyp
integer
Alias
- UMLS CUI [1]
- C0025677
Beschreibung
Mycophenolate mofetil / Mycophenolic acid
Datentyp
integer
Alias
- UMLS CUI [1]
- C0209368
- UMLS CUI [2]
- C0026933
Beschreibung
Sulfasalazine
Datentyp
integer
Alias
- UMLS CUI [1]
- C0036078
Beschreibung
Teriflunomide
Datentyp
integer
Alias
- UMLS CUI [1]
- C1718383
Beschreibung
Chemotherapeutics: Cytostatics
Alias
- UMLS CUI-1
- C0010858
- UMLS CUI-2
- C0729502
Beschreibung
Recent: Cladribine (2-CDA) i.v./s.c.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
- UMLS CUI [2,1]
- C0092801
- UMLS CUI [2,2]
- C0021499
- UMLS CUI [2,3]
- C0332185
Beschreibung
Recent: Cladribine (2-CDA) p.o.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0092801
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Beschreibung
Recent: Cyclophosphamide i.v.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0348016
- UMLS CUI [1,3]
- C0332185
Beschreibung
Recent: Cyclophosphamide p.o.
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0010583
- UMLS CUI [1,2]
- C0001563
- UMLS CUI [1,3]
- C0332185
Beschreibung
Recent: Mitoxantrone
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0026259
- UMLS CUI [1,2]
- C0332185
Beschreibung
Other Chemotherapeutics
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0729502
Beschreibung
Other Chemotherapeutics
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0205394
- UMLS CUI [1,2]
- C0729502
Beschreibung
Indicate other Chemotherapeutics
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0729502
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Beschreibung
Other immunosuppressive regimens: Corticosteroids
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0001617
Beschreibung
low dose prednisolone equivalent
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0445550
- UMLS CUI [1,2]
- C0038317
Beschreibung
medium dose prednisolone equivalent
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0439536
- UMLS CUI [1,2]
- C0178602
- UMLS CUI [1,3]
- C0038317
Beschreibung
high dose prednisolone equivalent
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0038317
- UMLS CUI [1,2]
- C0444956
Beschreibung
Other immunosuppressive regimens: Fumarate
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0220833
Beschreibung
Other immunosuppressive regimens: Immunoglobulines
Alias
- UMLS CUI-1
- C1963758
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0021081
Beschreibung
Other immunosuppressive regimens: Interferon
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C3652465
Beschreibung
Other immunosuppressive regimens: Other Multiple Sclerosis drugs
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C0205394
- UMLS CUI-3
- C0013227
- UMLS CUI-4
- C0026769
Beschreibung
Other immunosuppressive regimens
Alias
- UMLS CUI-1
- C0205394
- UMLS CUI-2
- C0021081
Beschreibung
Other immunosuppressive drugs
Datentyp
integer
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
Beschreibung
Indicate other immunosuppressive drugs
Datentyp
text
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C0205394
- UMLS CUI [1,3]
- C1521902
Beschreibung
Immunosuppressive drugs: Underlying disease
Alias
- UMLS CUI-1
- C0021081
- UMLS CUI-2
- C3146298
Beschreibung
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0026769
Beschreibung
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205494
- UMLS CUI [1,4]
- C0004364
- UMLS CUI [1,5]
- C0205394
Beschreibung
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0205478
Beschreibung
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0029216
Beschreibung
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C3495832
Beschreibung
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
Beschreibung
Please indicate the underlying disease which has lead to the use of the indicated treatments. E.g. a patient might has suffered from breast cancer but the immunosuppressive treatment is due to a rheumatic disease with a lower dosis than it would be used in case of anticancer treatment. In this case only rheumatic disease should be indicated.
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0277554
- UMLS CUI [1,4]
- C0205394
- UMLS CUI [1,5]
- C1521902
Beschreibung
Indication for immunosuppressive drugs: Unknown underlying disease
Datentyp
boolean
Alias
- UMLS CUI [1,1]
- C0021081
- UMLS CUI [1,2]
- C3146298
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0277554
Beschreibung
Is data entry for this section finished?
Alias
- UMLS CUI-1
- C4684556
- UMLS CUI-2
- C1828479
- UMLS CUI-3
- C0205197
Ähnliche Modelle
Immunosuppressive premedication
- StudyEvent: Baseline
- StudyEvent: Comorbidities and Pre-medication
- StudyEvent: Phases
- StudyEvent: Therapeutics
- StudyEvent: Diagnostics
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,2])
C0003241 (UMLS CUI-2)
C3160093 (UMLS CUI-2)
C0332185 (UMLS CUI [1,2])
C1564892 (UMLS CUI-2)
C2917367 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C0003241 (UMLS CUI-2)
C1521902 (UMLS CUI [1,2])
C0003241 (UMLS CUI [1,3])
C1622572 (UMLS CUI-2)
C1999216 (UMLS CUI-3)
C1521902 (UMLS CUI [1,2])
C0243077 (UMLS CUI [1,3])
C4733472 (UMLS CUI-2)
C3657270 (UMLS CUI [1,2])
C3658706 (UMLS CUI [1,2])
C1367202 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C1521902 (UMLS CUI [1,4])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C4733472 (UMLS CUI [1,3])
C0729502 (UMLS CUI-2)
C0026933 (UMLS CUI [2])
C0729502 (UMLS CUI-2)
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0092801 (UMLS CUI [2,1])
C0021499 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0348016 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0001563 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C0332185 (UMLS CUI [1,2])
C0729502 (UMLS CUI-2)
C0729502 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C0205394 (UMLS CUI-2)
C0001617 (UMLS CUI-3)
C0038317 (UMLS CUI [1,2])
C0178602 (UMLS CUI [1,2])
C0038317 (UMLS CUI [1,3])
C0444956 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C0220833 (UMLS CUI-3)
C0059764 (UMLS CUI [1,2])
C0633802 (UMLS CUI [2])
C0205394 (UMLS CUI-2)
C0021081 (UMLS CUI-3)
C0348016 (UMLS CUI [1,2])
C0021499 (UMLS CUI [1,2])
C0205394 (UMLS CUI-2)
C3652465 (UMLS CUI-3)
C0205394 (UMLS CUI-2)
C0013227 (UMLS CUI-3)
C0026769 (UMLS CUI-4)
C0021081 (UMLS CUI-2)
C0205394 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])
C1521902 (UMLS CUI [1,3])
C3146298 (UMLS CUI-2)
C3146298 (UMLS CUI [1,2])
C0026769 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0205494 (UMLS CUI [1,3])
C0004364 (UMLS CUI [1,4])
C0205394 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0205478 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0029216 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C3495832 (UMLS CUI [1,3])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C3146298 (UMLS CUI [1,2])
C0277554 (UMLS CUI [1,3])
C0205394 (UMLS CUI [1,4])
C1521902 (UMLS CUI [1,5])
C3146298 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0277554 (UMLS CUI [1,4])
C1828479 (UMLS CUI-2)
C0205197 (UMLS CUI-3)
C1828479 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])